ArticleWorld journal of virology2025
Predictors of sustained human immunodeficiency virus viral-load suppression before and after the adoption of Treat All policy in Rwanda.
Article in World journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSustained viral load (VL) suppression is an important indicator of successful treatment among people living with human immunodeficiency virus (HIV).
aimTo assess trends of different VL outcomes before and after adoption of the Treat All policy among people living with HIV in Rwanda
methodsBetween 2014 and 2017, VL suppression [VL suppression (VLS) < 200 copies/mL] was measured among people living with HIV from 28 healthcare facilities in Rwanda. Participant VL was measured at 6 months, 18 months, and 30 months. The unit of analysis was visit-pair, with subjects across four visit-pair categories: (1) Sustained VL suppression (VL < 200 copies/mL at two consecutive visits); (2) Persistent viremia (VL ≥ 200 copies/mL at two consecutive visits); (3) Viral rebound (VL < 200 copies/mL at prior visit only); and (4) Newly suppressed (VL < 200 copies/mL at subsequent visit only). Poisson regression models with generalized estimating equations were used to estimate adjusted incidence risk ratio (aIRR) and 95% confidence intervals (CIs) for factors associated with sustained VLS. To handle missing data, multiple imputations was performed.
resultsA total of 634 participants contributed 973 visit-pairs (295 single pairs and 339 double pairs). The median age was 37 years (interquartile range: 32-43 years). The incidence rates of sustained VLS, persistent viremia, viral rebound, and new suppression were 85.2%, 4.3%, 4.6%, and 5.7%, respectively. Young individuals aged 18-24 years had higher incidence of viral rebound compared to those 25 years or older (14.8%
conclusionAlthough most people living with HIV have sustained VLS in Rwanda, individuals without formal education, those presenting with advanced HIV, and younger individuals were lagging on multiple outcomes. Interventions tailored to these individuals would improve treatment outcomes to achieve epidemic control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.